Abstract: This invention relates to compositions and methods for the treatment or prophylaxis of glaucoma and ocular hypertension, and for lowering of intraocular pressure. The invention provide VEGFR-1 agonists and combinations of vascular endothelial growth factor B (VEGF-B) with placenta growth factor (PLGF), ‘ Secreted protein acidic cysteine-rich’ (SPARC) antagonists, insulin, insulin like growth factor, their isoforms, their analoges, their gene-engineered modifications. Furthermore, the formentioned compositions and combinations are provided for coadministration with antiglaucoma agents, currently in clinical use, for the treatment or prophylaxis of glaucoma and ocular hypertension, for lowering of intraocular pressure, for increasing success rate of surgical procedures for the treatment or prophylaxis of glaucoma, and for preserving retinal ganglion cells.

Abstract: This invention relates to compositions and methods for lowering intraocular pressure and treatment and/or prevention of glaucoma and ocular hypertension. The invention provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin peptide and other products of protein/gene engineered modifications of insulin for the lowering of intraocular pressure. The invention also provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein/gene engineered modifications of insulin for increasing the success of glaucoma surgical procedures. The invention further provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein/gene engineered modifications of insulin for neuroprotection of retinal ganglion cells.

Abstract: A method for targeting the central nervous system, for use in the treatment and/or prevention of central nervous system disorders and/or states, comprising administering to a subject in need of treatment an effective amount of a pharmaceutical composition by the ocular route of drug delivery.

Abstract: Provided is a method for enhanced intraocular drug penetration that comprises the co-administration of ocular therapeutics with agents that increases the permeability of ocular and periocular vessels and ocular epithelial barriers. Due to its unique and novel concept and additive nature, the method of the present invention can be used in combination with previous methods for enhancement of ocular drug penetration.

Abstract: A method for treatment or prevention of oral cavity diseases and disorders and/or related states, in a subject in need of such treatment, comprising local administration of antisecretory drugs and/or antacids, in acceptable pharmacological forms and pharmaceutical formulations.

Abstract: A method for targeting the central nervous system, for use in the treatment and/or prevention of central nervous system disorders and/or states, comprising administering to a subject in need of treatment an effective amount of a pharmaceutical composition by the ocular route of drug delivery.